LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of PresbyopiaGlobeNewsWire • 08/12/24
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024GlobeNewsWire • 08/07/24
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/08/24
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024GlobeNewsWire • 05/01/24
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia TrialsBusiness Wire • 04/03/24
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia TrialsBusiness Wire • 04/02/24
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate ProgressBusiness Wire • 03/21/24